3 stories mentioning SHA:688278Updated 8d ago
Every FINWIRES story that references SHA:688278, newest first.
China's National Medical Products Administration accepted Xiamen Amoytop Biotech's (SHA:688278) clinical trial application for ACT201 injection, according to a Shanghai bourse filing on Thursday.The drug, an antisense oligonucleotide drug, will be used as a treatment for hepatitis B.The drugmaker's shares rose 2% during the midday trade.
Xiamen Amoytop Biotech (SHA:688278) plans to raise funds of up to 1.53 billion yuan from the issuance of convertible bonds, according to a Thursday disclosure on the Shanghai bourse.The proceeds will be used to invest in a new drug research and development project, a biotechnology innovation center project and the construction of a production line.
Xiamen Amoytop Biotech (SHA:688278) signed an exclusive license agreement with Aligos Therapeutics for pevifoscorvir sodium, used for treating chronic hepatitis B.Amoytop will pay an upfront $25 million, plus up to $85 million in regulatory and $335 million in sales milestones, plus royalties, according to a Friday filing with the Shanghai bourse.The deal covers Mainland China, Hong Kong, Macao and Taiwan.Shares of the drugmaker closed 1% lower Friday.
